Cancer Immunotherapy News and Research

RSS

Cancer cells disarm cellular attackers by extending out nanoscale tentacles

To grow and spread, cancer cells must evade the immune system. Investigators from Brigham and Women's Hospital and MIT used the power of nanotechnology to discover a new way that cancer can disarm its would-be cellular attackers by extending out nanoscale tentacles that can reach into an immune cell and pull out its powerpack.

18 Nov 2021

Researchers develop a highly efficient method to generate immune cells for cancer therapies

A Ludwig Cancer Research study has devised a highly efficient method to generate large numbers of immune cells specifically engineered to recognize neoantigens-;small fragments of randomly mutated proteins that are typically unique to a patient's cancer-;and destroy the tumors that express them.

15 Nov 2021

Study points to a new, effective treatment option for patients with mesothelioma

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

8 Nov 2021

Key link between chronic stress and cancer discovered

Stress can have a significant negative effect on health, but our understanding of how stress impacts the development and progression of cancer is just beginning.

6 Nov 2021

Harvard researchers elucidate the underlying neuroanatomy of acupuncture

Acupuncture is a traditional Chinese technique that has been used for millennia to treat chronic pain and other health problems associated with inflammation, yet the scientific basis of the technique remains poorly understood.

2 Nov 2021

Immune checkpoint protein may be a promising new target for prostate cancer immunotherapy

The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center.

2 Nov 2021

Two new studies show how to enhance effectiveness of cancer immunotherapy

Two new studies revealed that anti-PD-1 immunotherapy given before surgery was safe and effective for patients with oral-cavity squamous cell carcinoma (OCSCC) and identified potential molecular biomarkers in the blood and tumors of patients that would show how likely it is that someone would respond to immunotherapy.

30 Oct 2021

UAB researchers show how to identify non-responding tumors and improve immunotherapy response

Immunotherapy using checkpoint inhibitors can work well to treat cancer, but only a minority of patients respond to therapy.

28 Oct 2021

New mechanisms for treating impregnable KRAS mutant cancers with statins

Third-generation cancer immunotherapy, a method of removing cancer using the body's immune system, has shown remarkable clinical benefits in recent years, giving hopes to many researchers and patients.

27 Oct 2021

Researchers discover new way to jump-start the immune system to attack tumors

Immunotherapy is a promising strategy to treat cancer by stimulating the body's own immune system to destroy tumor cells, but it only works for a handful of cancers.

19 Oct 2021

Researchers develop nanoparticles delivering STING agonists for intravenous cancer immunotherapy

Cancer immunotherapy seeks to turn "cold" tumors into "hot" tumors––those that respond to immunotherapy––by awakening and enlisting the body's own immune system.

30 Sep 2021

Novel strategy for in vitro cell-selective protection has potential for use in adoptive cell therapy

Adoptive cell therapy (ACT) is an emerging powerful cancerimmunotherapy, which includes a complex process of genetic modification, stimulation and expansion. During invitroorexvivomanipulation, sensitive cells are inescapably subjected to harmful external stimuli. Although a variety ofcytoprotectionstrategies have been developed, their application on ACT remains challenging.

29 Sep 2021

Study findings could lead to novel ways to overcome tumor resistance to immunotherapies

Cancer-fighting immune cells in patients with lung cancer whose tumors do not respond to immunotherapies appear to be running on a different "program" that makes them less effective than immune cells in patients whose cancers respond to these immune treatments, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy.

22 Sep 2021

Oxford COVID vaccine technology has the potential to revolutionize cancer treatment

Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the success of the Oxford-AstraZeneca vaccine against SARS-CoV-2 to develop a vaccine to treat cancer.

21 Sep 2021

Researchers reveal a mechanism of SHP2-mediated tumor immunosuppression

Colorectal cancer (CRC), a malignant tumor worldwide consists of microsatellite instability (MSI) and stable (MSS) phenotypes. Although SHP2 is a hopeful target for cancer therapy, its relationship with innate immunosuppression remains elusive. To address that, the authors of this article performed single-cell RNA sequencing to explore the role of SHP2 in all cell types of tumor microenvironment (TME) from murine MC38 xenografts.

21 Sep 2021

Scientists identify new approach to overcome resistance to cancer immunotherapy

Hokkaido University scientists and colleagues in Japan have found a way that could help some patients overcome resistance to immunotherapy treatment for cancer. The approach, proven in mice experiments, was reported in the Journal for Immunotherapy of Cancer.

17 Sep 2021

Skin cancer patients could have better prognosis with stronger T cell receptor signal strength

New research led by the University of Birmingham suggests that skin cancer patients could have a better prognosis if their T cells send messages from five specific genes in their immune response to drugs given to treat the disease.

17 Sep 2021

MD Anderson and SNIPR BIOME join forces to advance new CRISPR-based microbiome therapeutics

The University of Texas MD Anderson Cancer Center and SNIPR BIOME today announced a strategic collaboration to advance new CRISPR-based microbiome therapeutics to reduce immune-related adverse events (irAE) in patients being treated with combined immune checkpoint inhibitors.

13 Sep 2021

Eosinophils play a role in the battle against cancer metastases, study finds

A new study at Tel Aviv University found that eosinophils - a type of white blood cells - are recruited to the battle against cancer metastases in the lungs.